MAGEA3 and osteosarcoma: Among the five DE-ERSRGs, the Kaplan–Meier survival analysis suggested that osteosarcoma patients exhibiting high expression levels of BCL2, MAGEA3, MAP3K5, and TXNDC12 had significantly improved overall survival rates.